Core Viewpoint - Domestic pharmaceutical companies are intensifying competition in the GLP-1 market, particularly focusing on weight loss drugs, with Shijiazhuang Pharmaceutical Group making significant advancements in this area [1][2]. Group 1: Product Development and Clinical Trials - Shijiazhuang Pharmaceutical Group's subsidiary, Shijiazhuang Pharmaceutical Baike, has received regulatory acceptance for the new drug application of its innovative GLP-1 drug, Idaglutide α injection, aimed at long-term weight management in overweight or obese adults [1][2]. - The drug is based on a pivotal Phase III clinical trial involving overweight adults with at least one weight-related comorbidity, showing significant reductions in weight, waist circumference, blood sugar, blood pressure, and blood lipids compared to placebo [2][4]. - Idaglutide α injection is a recombinant human glucagon-like peptide-1 (hGLP-1) Fc fusion protein administered weekly, combining weight loss and blood sugar-lowering effects [1][2]. Group 2: Competitive Landscape - Idaglutide α injection is an innovative drug developed by Shijiazhuang Pharmaceutical Group, contrasting with the recently submitted application for the generic drug Semaglutide, highlighting the company's focus on original research [3][4]. - The competitive landscape includes multinational companies like Eli Lilly and Novo Nordisk, which are advancing next-generation weight loss therapies, shifting from single-target to multi-target approaches to enhance drug efficacy and safety [4][7]. - The global market for GLP-1 receptor agonists (GLP-1RA) is projected to reach $51.8 billion in 2024, with a 40% year-on-year growth, driven by significant demand in the weight loss segment [7]. Group 3: Future Prospects and Strategic Positioning - Shijiazhuang Pharmaceutical Group is also developing a long-acting GLP-1 drug, Semaglutide long-acting injection (SYH9017), which is expected to receive clinical approval for weight loss indications in December 2024 [5]. - The domestic weight loss drug market is becoming increasingly crowded, with multiple companies, including Shijiazhuang Pharmaceutical Group, submitting applications for Semaglutide, as the core patent for Novo Nordisk's Semaglutide is set to expire in 2026 [8].
又一款减重药要来了，石药GLP-1减重新药申报上市，全球多靶点竞速赛道拥挤